Compare Stocks

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
AKTX Akari Therapeutics	$1.19 +2.6%	$1.97	$1.08 ▼ $5.50	$9.43M	0.96	12,606 shs	7,932 shs
DMAC DiaMedica Therapeutics	$2.60 +9.7%	$2.87	$1.50 ▼ $4.75	$98.70M	1.69	43,155 shs	40,806 shs
TLGT Teligent		$0.03	$0.17 ▼ $1.60	N/A	N/A	N/A	6,460 shs
ZSAN Zosano Pharma	$0.00	$3.90	$0.46 ▼ $37.45	$1K	3.3	425,375 shs	5,685 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-88.23%
AKTX Akari Therapeutics	-3.33%	-10.77%	-41.12%	-59.30%	-70.15%
DMAC DiaMedica Therapeutics	-0.84%	-12.55%	-21.78%	-14.13%	+48.13%
TLGT Teligent	0.00%	0.00%	0.00%	0.00%	0.00%
ZSAN Zosano Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	0.9486 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.0	0.0
TLGT Teligent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	169.23% Upside
TLGT Teligent	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ZSAN, TLGT, DMAC, ADMP, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00

(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
TLGT Teligent	N/A	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	$790K	0.00	N/A	N/A	$9.74 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
AKTX Akari Therapeutics	-$10.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/6/2024 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
TLGT Teligent	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	-$29.92M	-$14.50	N/A	∞	N/A	-8,375.11%	-177.06%	-119.14%	N/A

Latest ZSAN, TLGT, DMAC, ADMP, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
AKTX Akari Therapeutics	N/A	0.95	0.95
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
TLGT Teligent	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	1.61	1.61

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
AKTX Akari Therapeutics	5.06%
DMAC DiaMedica Therapeutics	10.12%
TLGT Teligent	N/A
ZSAN Zosano Pharma	N/A

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
AKTX Akari Therapeutics	61.80%
DMAC DiaMedica Therapeutics	7.20%
TLGT Teligent	0.17%
ZSAN Zosano Pharma	2.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
AKTX Akari Therapeutics	15	7.92 million	3.03 million	Not Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
TLGT Teligent	2,357	N/A	N/A	Optionable
ZSAN Zosano Pharma	40	4.90 million	4.78 million	Not Optionable

ZSAN, TLGT, DMAC, ADMP, and AKTX Headlines

Source	Headline
	HOOK HOOKIPA Pharma Inc. seekingalpha.com - April 12 at 10:11 PM
	Nachrichten - Weitere Nachrichten wallstreet-online.de - January 9 at 2:39 PM
	LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan pbs.org - December 6 at 7:44 AM
	Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab n-tv.de - August 22 at 3:36 PM
	East Bay Business News bizjournals.com - May 18 at 9:49 PM
	Mankind Pharma IPO opens on April 25, listing scheduled for May 9 moneycontrol.com - April 27 at 4:20 PM
	Astellas Pharma forbes.com - April 6 at 12:00 PM
	Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation finance.yahoo.com - February 5 at 12:11 PM
	FTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders washingtonexaminer.com - January 23 at 3:25 PM
	Zosano Pharma Corporation (ZSANQ) ca.finance.yahoo.com - November 5 at 6:33 PM
	Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly endpts.com - October 13 at 11:22 AM
	Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants msn.com - October 12 at 2:32 PM
	Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims marketwatch.com - August 28 at 7:45 PM
	East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million bizjournals.com - August 27 at 4:10 PM
	Zosano Pharma Corp (ZSANQ) investing.com - August 25 at 12:28 AM
	East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M bizjournals.com - July 26 at 8:27 PM
	A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M. bizjournals.com - July 26 at 8:27 PM
	Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8 dbtnews.com - June 3 at 11:27 AM
	Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN marketwatch.com - June 2 at 3:26 PM
	Why Zosano Pharma Shares Are Getting Hammered Today msn.com - June 2 at 3:26 PM
	Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46% seekingalpha.com - June 2 at 10:26 AM
	Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN marketwatch.com - June 2 at 10:26 AM
	East Bay migraine patch developer files for bankruptcy bizjournals.com - June 2 at 10:26 AM
	Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Akari Therapeutics

NASDAQ:AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Teligent

NASDAQ:TLGT

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

Zosano Pharma

NASDAQ:ZSAN

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial